Switch theme
Sign up to access all valuation multiples
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
2016
24
LTM Revenue $13.4M
LTM EBITDA -$55.2M
$2.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Black Diamond Therapeutics has a last 12-month revenue of $13.4M and a last 12-month EBITDA of -$55.2M.
In the most recent fiscal year, Black Diamond Therapeutics achieved revenue of n/a and an EBITDA of -$78.4M.
Black Diamond Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Black Diamond Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$86.0M | -$78.4M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$91.2M | -$82.4M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Black Diamond Therapeutics's stock price is $1.
Black Diamond Therapeutics has current market cap of $79.3M, and EV of $2.9M.
See Black Diamond Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9M | $79.3M | XXX | XXX | XXX | XXX | $-1.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Black Diamond Therapeutics has market cap of $79.3M and EV of $2.9M.
Black Diamond Therapeutics's trades at 0.2x LTM EV/Revenue multiple, and -0.1x LTM EBITDA.
Analysts estimate Black Diamond Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Black Diamond Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBlack Diamond Therapeutics's NTM/LTM revenue growth is 148%
Black Diamond Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.3M for the same period.
Over next 12 months, Black Diamond Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Black Diamond Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Black Diamond Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Black Diamond Therapeutics acquired XXX companies to date.
Last acquisition by Black Diamond Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Black Diamond Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Black Diamond Therapeutics founded? | Black Diamond Therapeutics was founded in 2016. |
| Where is Black Diamond Therapeutics headquartered? | Black Diamond Therapeutics is headquartered in United States of America. |
| How many employees does Black Diamond Therapeutics have? | As of today, Black Diamond Therapeutics has 24 employees. |
| Who is the CEO of Black Diamond Therapeutics? | Black Diamond Therapeutics's CEO is Dr. Mark A. Velleca, M.D.. |
| Is Black Diamond Therapeutics publicy listed? | Yes, Black Diamond Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Black Diamond Therapeutics? | Black Diamond Therapeutics trades under BDTX ticker. |
| When did Black Diamond Therapeutics go public? | Black Diamond Therapeutics went public in 2020. |
| Who are competitors of Black Diamond Therapeutics? | Similar companies to Black Diamond Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Black Diamond Therapeutics? | Black Diamond Therapeutics's current market cap is $79.3M |
| What is the current revenue of Black Diamond Therapeutics? | Black Diamond Therapeutics's last 12-month revenue is $13.4M. |
| What is the current EBITDA of Black Diamond Therapeutics? | Black Diamond Therapeutics's last 12-month EBITDA is -$55.2M. |
| What is the current EV/Revenue multiple of Black Diamond Therapeutics? | Current revenue multiple of Black Diamond Therapeutics is 0.2x. |
| What is the current EV/EBITDA multiple of Black Diamond Therapeutics? | Current EBITDA multiple of Black Diamond Therapeutics is -0.1x. |
| Is Black Diamond Therapeutics profitable? | Yes, Black Diamond Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
